On Wednesday, Baird adjusted its stance on Medpace Holdings Inc . (NASDAQ: NASDAQ:MEDP), downgrading the stock from Outperform to Neutral and reducing the price target to $349 from the previous $413. The firm cited a shift in near-term expectations due to recent challenges faced by the company, despite its historically strong performance.
Medpace, known for its unique business model of offering full-service contracts exclusively to small- and mid-sized biotech clients, has experienced substantial growth, outstripping the Contract Research Organization (CRO) market with a 29% year-over-year revenue increase in 2023. The company's focus on organic growth and a robust financial standing, with no debt since the third quarter of 2023 and a strong cash flow, has been a cornerstone of its success.
However, Medpace has encountered headwinds, including elevated cancellations over the past three quarters, as some clients grapple with funding challenges. This has resulted in lower net book-to-bill (NBB) ratios than average in the second and third quarters of 2024. The company aims to achieve a more stable NBB ratio of 1.15x by the second half of 2025, but the near-term outlook remains pressured.
The revenue growth for Medpace is expected to slow down over the next three quarters, with low single-digit to mid-single-digit percentage growth forecasted for 2025. Despite this, the company is anticipated to maintain relatively strong margins, which is typical for Medpace in slower growth scenarios.
Given that CROs are primarily valued based on revenue growth and related key performance indicators, the current outlook and performance metrics suggest a less favorable position for Medpace in the near term, leading to the adjusted rating and price target by Baird.
In other recent news, Medpace experienced a shortfall in their third-quarter revenue, reporting $533.3 million, an 8.3% increase year-over-year but still below the anticipated $543.08 million. Despite this, Medpace exceeded earnings expectations with adjusted earnings per share at $3.01, surpassing the projected $2.78. TD Cowen maintains a Buy rating on Medpace, despite concerns over unusual cancellations in the quarter that may suggest deeper competitive challenges for the company.
For 2024, Medpace has adjusted its full-year guidance downwards, now projecting revenue between $2.09 billion and $2.13 billion, a figure below the $2.14 billion analysts had anticipated. The company's earnings per share are expected to range from $11.71 to $12.09, aligning with the consensus of $11.79. CEO August Troendle attributes the disappointing results to slower conversion of backlog and has indicated measures are being implemented to improve execution.
Recent developments also point to a 12.7% year-over-year decline in Medpace's net new business awards to $533.7 million in Q3, while the company's backlog saw an 8.8% growth to $2.93 billion. These developments, as analyzed by TD Cowen, may indicate broader industry trends and investor expectations.
InvestingPro Insights
Medpace Holdings Inc.'s recent performance and future outlook can be further illuminated by data from InvestingPro. Despite the challenges highlighted in Baird's downgrade, Medpace maintains a strong financial position. The company's revenue for the last twelve months as of Q3 2024 stood at $2.07 billion, with a robust revenue growth of 16.24% over the same period. This aligns with the article's mention of Medpace's substantial growth, outpacing the CRO market.
InvestingPro Tips indicate that Medpace operates with a moderate level of debt, which supports the article's statement about the company's strong financial standing. Additionally, the company's profitability over the last twelve months and analysts' predictions of continued profitability this year underscore its resilience in the face of current headwinds.
The P/E ratio (adjusted) of 27.71 and a PEG ratio of 0.82 suggest that while the stock may be trading at a premium compared to earnings, it could still be undervalued relative to its growth potential. This information provides context to Baird's decision to maintain a $349 price target despite the downgrade.
For investors seeking a more comprehensive analysis, InvestingPro offers 5 additional tips that could provide deeper insights into Medpace's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.